Rubicon Research Ltd
Incorporated in 1999, Rubicon Research Limited is a pharmaceutical company engaged in the development, manufacturing, & commercialization of differentiated formulations.[1]
- Market Cap ₹ 10,752 Cr.
- Current Price ₹ 653
- High / Low ₹ 672 / 571
- Stock P/E 118
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 19.0 %
- ROE 27.1 %
- Face Value ₹ 1.00
Pros
- Debtor days have improved from 184 to 129 days.
- Company's working capital requirements have reduced from 96.9 days to 56.5 days
Cons
- Company has a low return on equity of 8.12% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| 263 | 331 | 400 | 394 | 854 | |
| 173 | 220 | 360 | 375 | 699 | |
| Operating Profit | 90 | 111 | 40 | 18 | 155 |
| OPM % | 34% | 34% | 10% | 5% | 18% |
| 18 | 11 | 17 | 25 | 18 | |
| Interest | 6 | 9 | 9 | 19 | 31 |
| Depreciation | 18 | 28 | 32 | 36 | 39 |
| Profit before tax | 84 | 85 | 17 | -11 | 103 |
| Tax % | 29% | 38% | 1% | 53% | 12% |
| 59 | 53 | 17 | -17 | 91 | |
| EPS in Rs | 116.53 | 104.46 | 32.90 | -33.31 | 5.98 |
| Dividend Payout % | 2% | 0% | 0% | -2% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 37% |
| TTM: | 117% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 20% |
| TTM: | 638% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 8% |
| Last Year: | 27% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Equity Capital | 5 | 5 | 5 | 5 | 15 |
| Reserves | 350 | 406 | 424 | 281 | 370 |
| 30 | 93 | 169 | 320 | 425 | |
| 59 | 65 | 81 | 144 | 300 | |
| Total Liabilities | 445 | 570 | 678 | 750 | 1,109 |
| 151 | 177 | 181 | 199 | 307 | |
| CWIP | 2 | 4 | 3 | 25 | 10 |
| Investments | 35 | 32 | 19 | 0 | 0 |
| 256 | 356 | 476 | 526 | 793 | |
| Total Assets | 445 | 570 | 678 | 750 | 1,109 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| 9 | 47 | -71 | -75 | 21 | |
| -84 | -29 | -43 | -32 | -68 | |
| 76 | 52 | 65 | 123 | 44 | |
| Net Cash Flow | 1 | 70 | -49 | 16 | -4 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Debtor Days | 194 | 169 | 213 | 209 | 129 |
| Inventory Days | 360 | 373 | 203 | 609 | 421 |
| Days Payable | 213 | 212 | 206 | 353 | 247 |
| Cash Conversion Cycle | 341 | 330 | 210 | 465 | 302 |
| Working Capital Days | 191 | 168 | 159 | 75 | 57 |
| ROCE % | 21% | 5% | 1% | 19% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Acquisition
28 Oct - Rubicon to acquire up to ~10.5% of Neuronasal for up to USD 2.5M via milestones by March 31, 2027.
-
Announcement under Regulation 30 (LODR)-Acquisition
21 Oct - Advagen to acquire Gen1E preferred stock up to USD3M; $2M by Mar31,2026; $1M via milestones to Dec31,2027.
- Closure of Trading Window 17 Oct
- Listing of Equity Shares of Rubicon Research Ltd 16 Oct
Business Profile[1]
Rubicon Research Limited is a formulation-focused pharmaceutical company focusing predominantly on the United States. The company has established a strong presence in the US generic and specialty drug market, which contributed 99.5% of its revenue in Q1 FY26.